MARISA LIANG: Open Payments
NPI 1154712933 · GILROY, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$969 in 16 payments from 10 companies in 2025. Trend: 2023 $187 · 2024 $1,150 · 2025 $969
Food & beverage: $969
| Company | Payments | Amount |
|---|---|---|
| Ascendis Pharma Endocrinology Inc | 3 | $265 |
| Amgen Inc. | 3 | $255 |
| Lilly USA, LLC | 2 | $107 |
| Corcept Therapeutics | 1 | $105 |
| BETA BIONICS, INC. | 1 | $89 |
| AstraZeneca Pharmaceuticals LP | 1 | $55 |
| Novo Nordisk Inc | 2 | $32 |
| Madrigal Pharmaceuticals | 1 | $24 |
| Insulet Corporation | 1 | $23 |
| Novartis Pharmaceuticals Corporation | 1 | $15 |
Products named: Yorvipath, REPATHA, Korlym, iLet Bionic Pancreas, ZEPBOUND, MOUNJARO, REZDIFFRA, Omnipod.
Industry payments across CA — which companies pay providers there.
